Low-Grade Glioma Market Forecast 2026: Where the Industry Is Headed

Uncover key drivers, emerging technologies, and competitive movements shaping the low-grade glioma market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Low-Grade Glioma Market reach by 2030 starting from 2026 levels?

The low-grade glioma market has experienced significant expansion in recent years. It is anticipated to increase from $1.47 billion in 2025 to $1.56 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.9%. This historical growth can be linked to improvements in neuroimaging technologies, better survival rates for low-grade glioma patients, a rise in neurosurgical intervention procedures, increasing public awareness of brain tumor symptoms, and the proliferation of oncology treatment centers.

The low-grade glioma market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $1.94 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. This projected growth can be ascribed to an intensified emphasis on molecular tumor profiling, increased capital allocation towards targeted oncology medications, a rising preference for less invasive therapeutic alternatives, broadening availability of specialized neuro-oncology services, and continuous clinical investigations into new treatments. Key developments expected during this timeframe encompass a heightened emphasis on early detection and surveillance, an expanding embrace of targeted drug treatments, a growing inclination towards multi-modal therapeutic strategies, the broadening scope of individualized treatment blueprints, and the emergence of enhanced long-term disease management tactics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

Which Drivers Are Influencing Long-Term Growth In The Low-Grade Glioma Market?

The escalating occurrence of brain tumors is poised to stimulate the expansion of the low-grade glioma market moving forward. A brain tumor constitutes an abnormal cellular proliferation within the brain or its adjacent structures, which can be either benign or malignant. The surge in brain tumor incidence is attributable to factors such as elevated exposure to radiation, environmental contaminants, genetic predispositions, and the natural aging process. Low-grade glioma provides assistance for brain tumors by employing advanced diagnostic techniques and targeted interventions like surgery, radiation, and chemotherapy. These approaches are crucial for slowing tumor progression, preserving neurological function, and improving patient outcomes, highlighting the importance of early detection and individualized treatment for managing other brain tumors exhibiting similar growth characteristics. For instance, according to Cancer Australia, an Australia-based government agency, in October 2025, it was reported that Australia registered 1,597 deaths from brain cancer in 2023 (956 men and 641 women). By 2025, this number is projected to increase slightly to 1,639 deaths (979 men and 660 women). The estimated likelihood of death from brain cancer by age 85 in 2025 stands at 1 in 195 (0.51%), with the risk being higher for males at 1 in 165 (0.61%) and lower for females at 1 in 240 (0.42%). Hence, the rising incidence of brain tumors serves as a primary driver for the growth of the low-grade glioma market.

Which Segments Are Driving Activity In The Low-Grade Glioma Market?

The low-grade glioma market covered in this report is segmented –

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

2) By Treatment: Surgery, Chemotherapy, Radiation

3) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Trametinib: MEK Inhibitor Monotherapy, Combination Therapy (with BRAF Inhibitors)

2) By Dabrafenib: BRAF V600E–Mutant Low-Grade Glioma, Combination Therapy (with MEK Inhibitors)

3) By Ivosidenib: IDH1-Mutant Low-Grade Glioma, Oral Targeted Monotherapy

4) By Mirdametinib: NF1-Associated Low-Grade Glioma, MEK Inhibitor Monotherapy

What Trends Are Expected To Impact The Competitive Landscape Of The Low-Grade Glioma Market?

Companies active in the low-grade glioma market are increasingly prioritizing the integration of combination therapies and advanced targeted treatments, such as genetic alteration drugs. This approach aims to secure a competitive edge and elevate the standard of care for children affected by low-grade glioma. Genetic alteration drugs operate as targeted therapies specifically designed to modify or inhibit particular genetic mutations or cellular abnormalities, effectively assisting in the treatment of diseases like cancer by disrupting the pathways that drive uncontrolled cell proliferation. For instance, in May 2024, Day One Biopharmaceuticals, a US-based biotechnology company, launched Tovorafenib (Ojemda) following its accelerated FDA approval. This targeted therapy is designated for children aged six months and older who have unresectable or recurrent low-grade glioma (LGG) with BRAF gene alterations. As a convenient once-weekly oral treatment, it fulfills a critical requirement for pediatric LGG patients who previously had limited treatment alternatives.

Which Key Players Are Driving Competition In The Low-Grade Glioma Market?

Major companies operating in the low-grade glioma market are F Hoffmann La Roche Ltd, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co Inc, Ipsen SA, Agios Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, Les Laboratoires Servier, BeiGene Ltd, Daiichi Sankyo Company Limited, AnHeart Therapeutics Inc, Apollomics Inc, CStone Pharmaceuticals Co Ltd, Avistone Biotechnology Co Ltd, Blueprint Medicines Corporation, Revolution Medicines Inc, SpringWorks Therapeutics Inc, Exelixis Inc, Genentech Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

Which Region Currently Holds The Largest Share Of The Low-Grade Glioma Market?

North America was the largest region in the low-grade glioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Low-Grade Glioma Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21215&type=smp

Browse Through More Reports Similar to the Global Low-Grade Glioma Market 2026, By The Business Research Company

Pontine Glioma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pontine-glioma-drugs-global-market-report

Adult Malignant Glioma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Glioblastoma Multiforme Market Report 2026

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795